{"url_path":"/sec/eldn/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221658-index.html","accession_number":"0001193125-26-221658","cik":"0001404281","ticker":"ELDN","issuer_name":"Eledon Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1404281/0001193125-26-221658-index.html","primary_entity_key":"0001404281","primary_entity_name":"Eledon Pharmaceuticals, Inc."},"word_count":131,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 13, 2026, Eledon Pharmaceuticals, Inc. (the “Company”) issued a press release regarding its quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1.\n\nThe information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}